Compounds having the structure of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent cyclin-dependent kinase 2 (CDK2)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.